Positive Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising HELIOS Trial Results for AMX0035

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX – Research Report), with a price target of $16.00.

Andrew Fein has given his Buy rating due to a combination of factors related to the promising data from the HELIOS trial for Amylyx Pharmaceuticals Inc. The trial results demonstrated a significant improvement in C-peptide levels, which are crucial for assessing pancreatic beta cell function, indicating that the drug AMX0035 may slow disease progression in Wolfram syndrome patients. Additionally, the trial showed positive changes in HbA1c levels, suggesting improved glycemic control, which is a critical aspect of managing the disease.
Moreover, the trial also reported improvements in visual acuity, reinforcing the potential neuroprotective effects of AMX0035. The sustained metabolic and visual improvements observed in the trial support the potential for AMX0035 to modify the disease course in Wolfram syndrome. The preparation for a Phase 3 trial with the FDA further underscores the drug’s potential, and the rarity of the condition suggests that the pivotal study may be relatively small and focused. These factors combined contribute to Fein’s positive outlook and Buy rating for Amylyx Pharmaceuticals Inc.

In another report released on May 9, Leerink Partners also reiterated a Buy rating on the stock with a $10.00 price target.